When Life Sciences Marketing Practices Require Investigation: Off-Label Promotion, HCP Arrangements, and Anti-Kickback Risk

Marketing and promotional activity in life sciences and digital health companies often sits at the intersection of commercial strategy, clinical evidence, regulatory requirements, and healthcare fraud and abuse risk.

Most promotional issues do not begin as obvious compliance failures. They often surface through a sales deck, a field communication, a speaker program, a consulting arrangement, a discounting strategy, or questions about how medical affairs is interacting with healthcare professionals. At the outset, the issue may appear to be a routine marketing or training concern. Over time, however, the surrounding facts can change the analysis.

The key question is not only what was said or done. It is how the conduct operated in context, who was involved, what incentives existed, and whether the activity could be viewed as influencing clinical or purchasing decisions in a way that creates regulatory exposure.

How Promotional Issues Typically Surface

Promotional conduct concerns often arise through routine compliance monitoring, medical/legal/regulatory review, employee complaints, competitor activity, payer inquiries, or questions raised by legal, compliance, or medical affairs. In some cases, they emerge during diligence, when a company’s commercial practices are reviewed more closely by investors, buyers, or strategic partners.

The issue may begin with a claim that appears broader than the available support. It may involve sales personnel discussing product uses that are not reflected in labeling or approved materials. It may involve a field practice that differs from the company’s formal policy. In other cases, the concern may relate less to what was said and more to how healthcare professionals were engaged, compensated, or encouraged to use or recommend a product.

These issues often require more than reviewing the final approved marketing material. The analysis may need to consider emails, training materials, call notes, speaker program records, consulting agreements, discounting practices, and the interaction between commercial teams and medical affairs.

Sales Influence and the Role of Medical Affairs

Medical affairs plays an important role in life sciences companies. Its function is distinct from sales and marketing, particularly when engaging in scientific exchange, responding to unsolicited requests, or supporting education about clinical data.

Risk increases when that separation becomes blurred. If sales personnel influence medical affairs decisions, steer scientific discussions toward commercial objectives, or use medical affairs as a way to support sales strategy, the activity may warrant closer review. The concern is not simply whether medical affairs personnel were involved. It is whether their involvement was independent, scientifically grounded, and consistent with the company’s policies and regulatory obligations.

This can become particularly sensitive where medical affairs activity is used to support product adoption, expand utilization, or address commercial objections in the field. Even where the underlying information is accurate, the context in which it is delivered can affect how the conduct is evaluated.

Free or Discounted Products

Free or discounted products can serve legitimate business purposes, including product evaluation, patient access, contracting, or market entry. But they can also create risk where they are used to influence purchasing, prescribing, ordering, or referral decisions. The analysis often depends on the structure and purpose of the arrangement. A limited evaluation program with defined criteria, documented controls, and clear separation from purchasing decisions looks different from a practice in which free products are offered selectively to high-value accounts or tied to expected future business.

Discounting can raise similar issues. Discounts that are properly structured, documented, and reported may be appropriate. But inconsistent discounts, undocumented exceptions, or discounts tied to utilization expectations can raise questions about whether the arrangement is functioning as an improper inducement.

These issues are especially sensitive when products are used by providers who bill federal healthcare programs. In that context, promotional activity can quickly intersect with Anti-Kickback Statute and False Claims Act considerations.

Consulting Arrangements with Healthcare Professionals

Consulting arrangements with healthcare professionals are common in life sciences and digital health. Companies often need input from physicians, researchers, and other clinical experts to support product development, clinical strategy, education, and market understanding.

The risk arises when those arrangements are not clearly tied to legitimate services, when compensation is difficult to support, or when the relationship appears connected to prescribing, ordering, purchasing, or referral behavior. A consulting agreement may look appropriate on paper, but the operational reality matters. Were services actually performed? Were they documented? Was compensation consistent with fair market value? Were consultants selected based on expertise, or based on commercial value to the company? These questions become more important where the healthcare professional is a key customer, high-volume user, or influential voice in a target market. In those situations, the arrangement may require a structured review to determine whether it reflects a legitimate consulting relationship or creates broader compliance risk.

Speaker Programs

Speaker programs remain a common area of scrutiny because they combine education, compensation, hospitality, and customer engagement. Properly structured programs can serve legitimate educational purposes. Poorly controlled programs can create risk if they function primarily as a way to reward or influence healthcare professionals.

Issues may arise where speakers are selected based on prescribing or purchasing volume, where attendance is low or repetitive, where meals or hospitality appear excessive, or where the same healthcare professionals attend similar programs repeatedly. Risk may also increase where the content is not meaningfully educational or where sales personnel exert too much control over speaker selection, audience composition, or program messaging. The concern is not simply whether a speaker program exists. It is whether the program operates as a bona fide educational activity or whether the surrounding facts suggest a commercial purpose inconsistent with compliance expectations.

Off-Label Promotion Risk

Off-label promotion concerns often require careful factual review because the line between permissible scientific exchange and impermissible promotion can be highly context dependent.

A company may have legitimate scientific information about uses, patient populations, dosing, features, or outcomes that are not fully reflected in approved labeling or cleared indications. The risk arises when that information is used by commercial teams to drive adoption outside the approved or cleared use, particularly through sales conversations, training materials, objection handling documents, or informal communications.

Off-label risk can also emerge indirectly. A marketing claim may not expressly promote an unapproved use, but the audience, context, and surrounding messaging may suggest a broader intended use. Similarly, medical affairs responses to unsolicited requests may be appropriate in isolation, but become problematic if sales personnel are involved in generating, directing, or exploiting those requests.

When off-label concerns arise, the investigation often needs to evaluate not only the content of communications, but also the process that produced them, the channels through which they were distributed, and the commercial incentives surrounding their use.

Seeding the Market Risk

Seeding the market risk arises when activity that appears educational, evaluative, or research-oriented is actually designed to drive future commercial adoption. This can occur through free product programs, pilot arrangements, early access initiatives, investigator relationships, advisory boards, or consulting engagements.

The issue is not whether a company may introduce a product to the market or gather feedback from healthcare professionals. Those activities can be legitimate and important. The concern arises when the structure suggests that the purpose is to cultivate future purchasing behavior, normalize use before sufficient support exists, or create momentum with influential healthcare professionals in a way that is not adequately controlled or documented.

For digital health companies, this risk can appear in pilot programs, unpaid deployments, preferred access arrangements, or collaborations with providers that later become paying customers. For medical device and pharmaceutical companies, it may arise through evaluation units, advisory programs, or clinical engagement strategies that appear closely tied to commercial objectives.

These arrangements often require close review because the documents may describe one purpose while the surrounding communications suggest another.

When a Marketing Concern Becomes Investigative

Not every promotional concern requires a formal investigation. Some issues can be addressed through training, corrective review, or revisions to materials and processes.

The analysis changes when the concern appears repeated, intentional, widespread, or connected to sales incentives. A single unclear statement in a draft deck is different from a field practice that has been adopted across a sales team. A one-off documentation gap is different from a pattern of HCP arrangements that appear tied to commercial value. A narrow question about a claim is different from evidence that medical affairs, consulting arrangements, or product discounts are being used to influence customer behavior.

At that point, the organization needs to understand scope, intent, operational reality, and potential downstream exposure. The process itself becomes important because the company may later need to explain not only what happened, but how it evaluated and addressed the issue.

Taking a Structured Approach

A structured review should begin by defining the concern and identifying the relevant business functions involved. Promotional conduct issues often cut across sales, marketing, medical affairs, compliance, legal, finance, and business leadership. Without a clear scope, the review can become fragmented or incomplete.

The next step is to evaluate the relevant materials and conduct in context. That may include approved marketing materials, draft materials, training decks, field guidance, emails, call notes, CRM records, speaker program documentation, consulting agreements, discount approvals, and communications involving medical affairs. The purpose is to determine whether the issue is isolated, whether it reflects a broader practice, and whether the company’s controls operated as intended.

Where the issue appears limited, corrective action may be sufficient. Where the review identifies systemic conduct, improper influence, off-label activity, problematic HCP arrangements, or potential inducement concerns, a more comprehensive investigation may be warranted.

The objective is not simply to determine whether a policy was violated. It is to understand how the conduct functioned in practice and whether it created regulatory, enforcement, or reputational risk.

Key Takeaways

• Promotional conduct concerns often surface through routine reviews, employee complaints, field activity, or questions about HCP engagement

• Risk frequently depends on context, including who was involved, what incentives existed, and how the activity operated in practice

• Sales influence over medical affairs, speaker programs, consulting arrangements, discounts, and free product programs can create significant compliance concerns

• Off-label promotion risk may arise through formal materials, informal field communications, or the misuse of medical affairs channels

• Seeding the market concerns require careful review of whether educational, evaluative, or research-oriented activity is actually serving a commercial adoption strategy

• A structured assessment helps determine whether the issue is limited or whether a broader investigation is warranted

Marketing and promotional activity is essential to life sciences and digital health companies. The challenge is recognizing when commercial activity begins to create compliance risk that cannot be resolved through routine review alone.

That determination often depends less on any single communication and more on the broader context in which the activity occurred. When sales practices, medical affairs activity, HCP arrangements, discounts, or product access programs begin to point in the same direction, a structured investigation may be necessary to understand the true scope of the risk.